Hpv Vaccine After Removing Precancerous Cells Can Reduce The Risk Of Cervical Cancer Health

Cases of cervical cancer in the UK have fallen significantly since 13- and 14-year-old students – first girls and later boys – began being offered HPV vaccines in 2008 to protect against the disease. However, new findings suggest that the vaccine may have a second key role in preventing cervical cancer. British researchers believe that giving women a dose during surgery to remove precancerous cells could prevent them from coming back. “HPV vaccination is highly effective in preventing the development of precancerous lesions of the cervix (cervical intraepithelial neoplasia or CIN),” according to their findings, which have been published in the British Medical Journal. CIN means that abnormal changes of the cells lining the cervix have been detected. If left untreated, they can develop into cervical cancer. There are three forms of CIN, known as CIN1, 2 and 3. The study team, led by Maria Kyrgiou of Imperial College London, analyzed 18 previous papers on the topic. They found that people who had been vaccinated against HPV had a 57% lower risk of recurrence of high-grade preinvasive disease (CIN2+) than those who had not had the vaccine. The risk dropped even further – 74% – when the odds of CIN2+ recurrence were assessed for HPV16 and HPV18, the two types of virus that cause many cases of cervical cancer. However, the authors stressed that the evidence for these reductions was “unclear” and that large-scale randomized control trials were needed to confirm that vaccination provided this benefit. “We are pleased to see emerging research on the value of using the HPV vaccine to prevent the recurrence of cervical cell changes and look forward to further large-scale studies of the effectiveness of this method,” said Eluned Hughes. , chief intelligence officer. and commitment to Jo’s Cervical Cancer Trust. While HPV vaccines have reduced cervical cancer cases by 87% since 2008, women over 27 who could not get it are still at increased risk of developing the disease. Alice Davies, health information manager at Cancer Research UK, was cautious about the findings. “This study looked at whether the HPV vaccine can stop further cell changes that occur after people have undergone treatment to remove abnormal cells caused by HPV infection. But it is still too early to say whether using the vaccine in this way is beneficial, and larger studies and high-quality trials are needed.”

title: “Hpv Vaccine After Removing Precancerous Cells Can Reduce The Risk Of Cervical Cancer Health " ShowToc: true date: “2022-12-08” author: “Andrew Wolfe”

Cases of cervical cancer in the UK have fallen significantly since 13- and 14-year-old students – first girls and later boys – began being offered HPV vaccines in 2008 to protect against the disease. However, new findings suggest that the vaccine may have a second key role in preventing cervical cancer. British researchers believe that giving women a dose during surgery to remove precancerous cells could prevent them from coming back. “HPV vaccination is highly effective in preventing the development of precancerous lesions of the cervix (cervical intraepithelial neoplasia or CIN),” according to their findings, which have been published in the British Medical Journal. CIN means that abnormal changes of the cells lining the cervix have been detected. If left untreated, they can develop into cervical cancer. There are three forms of CIN, known as CIN1, 2 and 3. The study team, led by Maria Kyrgiou of Imperial College London, analyzed 18 previous papers on the topic. They found that people who had been vaccinated against HPV had a 57% lower risk of recurrence of high-grade preinvasive disease (CIN2+) than those who had not had the vaccine. The risk dropped even further – 74% – when the odds of CIN2+ recurrence were assessed for HPV16 and HPV18, the two types of virus that cause many cases of cervical cancer. However, the authors stressed that the evidence for these reductions was “unclear” and that large-scale randomized control trials were needed to confirm that vaccination provided this benefit. “We are pleased to see emerging research on the value of using the HPV vaccine to prevent the recurrence of cervical cell changes and look forward to further large-scale studies of the effectiveness of this method,” said Eluned Hughes. , chief intelligence officer. and commitment to Jo’s Cervical Cancer Trust. While HPV vaccines have reduced cervical cancer cases by 87% since 2008, women over 27 who could not get it are still at increased risk of developing the disease. Alice Davies, health information manager at Cancer Research UK, was cautious about the findings. “This study looked at whether the HPV vaccine can stop further cell changes that occur after people have undergone treatment to remove abnormal cells caused by HPV infection. But it is still too early to say whether using the vaccine in this way is beneficial, and larger studies and high-quality trials are needed.”